Ventripoint Issues Shares for Payment of Debenture Interest

Core Insights - Ventripoint Diagnostics Ltd. has received approval from the TSX Venture Exchange to issue 1,164,044 common shares to satisfy $104,752 in interest payments on outstanding Convertible Debentures [1] - The Convertible Debentures carry an interest rate of 10% per annum, with interest payable every six months [1] - The shares will be issued at a deemed price of $0.09 and are subject to a hold period of four months and one day [1] Company Overview - Ventripoint is a leader in AI-enhanced cardiac imaging solutions, specifically in the application of AI to echocardiography [3] - The company's VMS+™ products utilize proprietary knowledge-based reconstruction technology, providing accurate volumetric cardiac measurements comparable to MRI [3] - Ventripoint's technology is an affordable alternative that enhances cardiologists' confidence in patient management and is compatible with all ultrasound systems from various vendors [3]